Acumen reports Q2 2025 financial results, cash at $166.2mln.

• Acumen Pharmaceuticals reports Q2 2025 financial results • ALTITUDE-AD Phase 2 study topline results expected in late 2026 • Decision to advance oligomer-targeted product candidate in early 2026 • Cash and securities of $166.2 million as of June 30, 2025 • Expected to support activities into early 2027 • Conference call and webcast today at 8:00 a.m. ET.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has reported its second-quarter (Q2) 2025 financial results, highlighting significant progress in its pipeline and operational activities. The company's financial report, released on August 12, 2025, provides insights into its financial health and strategic initiatives.

Financial Highlights

- Cash Balance: As of June 30, 2025, Acumen reported $166.2 million in cash, cash equivalents, and marketable securities, down from $197.9 million at the end of March 2025. This decrease is attributed to ongoing operational expenses and clinical trial costs [1].
- Research and Development (R&D) Expenses: R&D expenses for the three-month period ended June 30, 2025, were $37.1 million, a significant increase from $19.5 million in the same period of 2024. This increase is primarily due to higher manufacturing and materials costs, as well as increased costs associated with the ALTITUDE-AD clinical trial [1].
- General and Administrative (G&A) Expenses: G&A expenses decreased to $4.6 million from $4.8 million in the same period of 2024, primarily due to minor decreases in insurance and recruiting costs [1].
- Loss from Operations: The company reported a loss from operations of $41.8 million for the three-month period ended June 30, 2025, up from $24.4 million in the same period of 2024. This increase is primarily due to the higher R&D expenses [1].
- Net Loss: Acumen reported a net loss of $41.0 million for the three-month period ended June 30, 2025, up from $20.5 million in the same period of 2024 [1].

Clinical and Business Updates

Acumen's CEO, Daniel O’Connell, highlighted the company's continued momentum in the second quarter, driven by strong operational execution and the addition of the Enhanced Brain Delivery (EBDTM) program. The company expects topline results from its ALTITUDE-AD Phase 2 study in late 2026 and anticipates a decision to advance an oligomer-targeted EBD product candidate in early 2026. The company has also announced a collaboration with JCR Pharmaceuticals to develop an EBD therapy for Alzheimer's disease [1].

Upcoming Events

Acumen will host a conference call and live audio webcast today, August 12, 2025, at 8:00 a.m. ET, to discuss these financial results and business updates. Investors and financial professionals are encouraged to register in advance to participate [1].

References

[1] https://www.biospace.com/press-releases/acumen-pharmaceuticals-reports-second-quarter-2025-financial-results-and-business-highlights